A meta-analysis favored ketamine for selected suicidal-ideation outcomes, but midazolam’s role was to support a controlled comparison.
Ten randomized trials involving 649 adults compared ketamine with midazolam. The synthesis reported greater reductions in suicidal-ideation and depression scores with ketamine, alongside more frequent selected adverse effects. Midazolam was used as a sedating active comparator to help control nonspecific acute effects and masking.
Outcome scales, timing, and study methods varied, and certainty was limited for some comparisons. An active control is not necessarily an established treatment for the target condition. The study did not establish prevention of suicide death or long-term superiority across all patients.
In expert explanation, distinguish symptom-score changes from suicide attempts and deaths. These trials do not demonstrate that benzodiazepines treat acute suicidality or that they caused the comparison group’s symptoms. The comparator’s methodological purpose is essential to interpreting the result.
Source reviewed: Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality A GRADE Assessed System (PMC12883703). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Etomidate–Midazolam Versus Propofol–Ketamine in Patients With Reduced Ejection Fraction; TAS-115 Interaction Study Used Swallowed Midazolam as a CYP3A Probe.